The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
Review | Cancer Focus| August 12 2024 In Special Collection: Mechanisms and Models of Cancer 2024 Mark Esposito, John K. Amory, Yibin Kang J Exp Med (2024) 221 (9): e20240519. https://doi.org/10.1084/jem.20240519
Join us at BioNJ BioPartnering
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at BioNJ BioPartnering on May 14th.
Join us at Life Science Innovation Northwest 2024
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at Life Science Innovation Northwest (LSINW) 2024 on April 18th at 11:05 AM - 12:15 PM.
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
Washington state backs AI-driven cancer diagnostics and other startup projects
Washington state backs AI-driven cancer diagnostics and other startup projects – GeekWire
KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million
New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...
Kayothera Announces Expansion to Type 2 Diabetes with New Pipeline Addition
Kayothera announces new pipeline expansion in Cardiometabolic diseases with a focus on Type 2 Diabetes
Kayothera Founder Presented with Princeton University’s Tiger Entrepreneur Award
Princeton Entrepreneurship Council is pleased to announce the winners of the 2022 Tiger Entrepreneur Award. For the last six years, the Tiger Entrepreneur Award has been given to celebrate the value of entrepreneurship across the Princeton community and to emphasize...
KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics
Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of...
KayoThera selected as a finalist in TechUnited’s Propelify Event
Kayothera was selected as one of four finalists in this year's Propelify event, a premier event celebrating technology and innovation in the tri-state area. Kayothera will be pitching at the BetterWellness challenge at 1:10 pm on October 6. The judges will award two...
BIO Announces KayoThera as the 2021 Start-up Stadium Winner
The Biotechnology Innovation Organization (BIO) today announced that Kayothera Inc. is the winner of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 16 finalists were evaluated by expert judges with...
Kayothera selected as finalist in BIO’s Start-up Stadium
Kayothera will be presenting on their novel immune oncology pipeline during the week of June 10 at BIO's annual meeting. Pitches for the Startup Stadium will go live on Thursday followed by voting.
KayoThera to graduate from Endless Frontier Labs Accelerator
KayoThera has taken part in the NYU Stern Business School Endless Frontier Labs accelerator program since October 2020 to refine the business plan and expand the company trajectory and growth initiatives. This accelerator was exceptionally valuable to the development...
KayoThera founders publish Nature Cancer review on new therapeutic strategies to treat incurable cancers
Announcing a new review on emerging strategies to treat advanced cancers published in Nature Cancer.
KayoThera founders announce discovery of a new organelle driving cancer metastasis
In the cover article of the March issue of Nature Cell Biology, Dr. Mark Esposito and Dr. Yibin Kang announce the discovery of a novel driver of breast and prostate cancer metastasis. This newly discovered organelle is driven by a relatively unknown protein named...